A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules

Chest

Volumn 117, Issue 5, 2000, Pages 1232-1238

  Blum, Jay ^a   Handmaker, Hirsch ^b,d   Lister James, John ^c   Rinne, Neal ^a  

^a Cigna   (United States)

^b Arizona Inst of Nucl Med/H   (United States)

^c BAYER PHARMA AG   (Germany)

^d Healthcare Technology Group   (United States)

Author keywords

Fluorine 18 fluorodeoxyglucose positron emission tomography; Single photon emission CT; Solitary pulmonary nodules; Somatostatin; 111indium DTPA D Phe1 octreotide

Indexed keywords

DEPREOTIDE TC 99M; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NODULE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY;

EID: 0034078509     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.5.1232     Document Type: Article

References (45)

1. 1 Gazdar AF, Minna JD. Cigarettes, sex and lung adenocarcinoma. J Natl Cancer Inst 1997; 89:1563-1565
2. 2 Liu BQ, Peto R, Chen ZM, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 1998; 317:1411-1422
3. 3 Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998; 48:6-9
4. 4 Swenson S, Silverstein M, Ilstrup D, et al. The probability of malignancy in solitary pulmonary nodules. Arch Intern Med 1997; 157:849-855
5. 5 Good C, Wilson T. The solitary circumscribed pulmonary nodule: study of 7 years JAMA 1958; 166:210-215
6. 6 Siegelman S, Khouri N, Leo F, et al. Solitary pulmonary nodules: CT assessment. Radiology 1986; 160:307-312
7. 7 Katz S, Peabody J, Davis E. The solitary pulmonary nodule. Dis Mon 1961; 7:3-38
8. 8 Dholakia S, Rappaport D. The solitary pulmonary nodule. Postgrad Med 1996; 99:246-250
9. 9 Ginsberg MS, Griff SK, Go BM, et al. Lung nodules resected at video-assisted thoracoscopic surgery (VATS): etiology in 437 patients [abstract]. Radiology 1998; 209(suppl):223
10. 10 Read C. Coin lesion, pulmonary: in the southwest. Ariz Med 1972; 29:775-781
11. 11 Viggiano R, Swenson S, Rosenow E. Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 1992; 13:83-94
12. 12 Dewan N, Shehan C, Reeb S, et al. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997; 112:416-422
13. 13 Garland L. Studies on the accuracy of diagnostic procedures. AJR Am J Roentgenol 1959; 82:25-53
14. 14 Kundel H,. Perception errors in chest radiography. Semin Respir Med 1989; 10:203-210
15. 15 Yamashita K, Matsunobe S, Tsuda T, et al. Solitary pulmonary nodule: preliminary study of evaluation with incremental dynamic CT. Radiology 1995; 194:399-405
16. 16 Swenson S, Brown L, Colby T, et al. Pulmonary nodules: CT evaluation of enhancement with iodinated contrast material. Radiology 1995; 194:393-398
17. 17 Funatiashi A, Browne T, Houser W, et al. Diagnostic value of bronchial aspirate and postbronchoscopic sputum in fiberoptic bronchoscopy. Chest 1979; 76:514-517
18. 18 Frey WC, Arendt WF, Williams JB, et al. Evaluation of the solitary pulmonary nodule by dynamic spiral CT [abstract]. Chest 1998; 114(suppl):305S-306S
19. 19 Rafanan AL, Mehta AC. Role of bronchoscopy in the evaluation of a solitary pulmonary nodule. In: Nelson S, ed. Mediguide to Pulmonary Medicine. New York, NY: Lawrence DellaCorte Publications, 1998; 1-6
20. 20 Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. Nucl Med Annu 1995; 1995:1-50
21. 21 O'Byrne KJ, Carney DN. Radiolabeled somatostatin analogue scintigraphy in oncology. Anticancer Drugs 1996; 7(suppl 2):33-44
22. 22 Kwekkeboom DJ, Kho GS, Lamberts SW, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 221:1106-1113
23. 23 Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36:1825-1835
24. 24 O'Byrne K, Carney D. Somatostatin and the lung. Lung Cancer 1993; 10:151-172
25. 25 Virgolini I, Pangerl T, Bischof C, et al. Somatostatin receptor expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Invest 1997; 27:645-647
26. 26 Krenning E, Kwekkeboom D, Bakker W. Somatostatin receptor scintigraphy with [111In-DTPA-D-PHE1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731
27. 27 Blum J, Handmaker H, Rinne N. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 1999; 115:224-232
28. 28 Handmaker H, Mohler K, Dann R, et al. Oncoscintigraphy of neuroendocrine and non-neuroendocrine tumors with a novel SSR binding peptide: technetium Tc-99m P829; preliminary experience in 39 patients [abstract]. Clin Nuc Med 1997; 22:350
29. 29 Vallabhajosula S, Moyer B, Lister-James J. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996; 27:1016-1022
30. 30 Cummings S, Lillington G, Richard R. Estimating the probability of malignancy in solitary pulmonary nodules. Am Rev Respir Dis 1986; 134:449-452
31. 31 Lillington G. The solitary pulmonary nodule 1974. Am Rev Respir Dis 1974; 110:699-706
32. 32 Wynder E, Mabuchi K, Beattie E. The epidemiology of lung cancer: recent trends. JAMA 1970; 213:2221-2228
33. 33 Fleiss J. Statistical methods of rate and proportion. 2nd ed. New York, NY: John Wiley, 1981; 217-230
34. 34 Kazerooni E, Lim T, Mikhail A, et al. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology 1996; 198:371-375
35. 35 Shreve PD, Steventon RS, Deters EC, et al. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual head coincidence gamma camera versus positron emission tomographic scanner. J Nucl Med 1998; 207:431-437
36. 36 Templeton A, Jansen C, Lehr J, et al. Solitary pulmonary lesions: computer aided differential diagnosis and evaluation of mathematical methods. Radiology 1967; 89:605-613
37. 37 Edwards F, Schaefer P, Callahan S, et al. Bayesian statistical theory in the preoperative diagnosis of pulmonary lesions. Chest 1987; 92:888-891
38. 38 Gurney J, Lyddon D, McKay J. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Radiology 1993; 186:415-422
39. 39 Wojtowicz J, Pietraszkiewicz L, Grala B. A trial of differential diagnosis of solitary pulmonary foci on the basis of Bayes's equation with the use of electronic digital computers. Pol Rev Radiol Nucl Med 1970; 34:684-69
40. 40 Fujitu T, Yamaji Y, Sato M. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2 in human lung cancer lines. Life Sci 1994; 55:1797-1806
41. 41 Lamberts S, Van Der Lely A, de Herder W, et al. Octreotide. N Engl J Med 1996; 34:246-254
42. 42 Reubi JC, Krenning E, Lamberts SWJ, et al. In vitro detection of somatostatin receptors in human tumors. Metabolism 1992; 41(suppl 2):104-110
43. 43 Lowe V, Fletcher J, Gobar L, et al. Prospective investigation of position emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084
44. 44 Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109:982-988
45. 45 Gambhir S, Shepherd J, Handmaker H, et al. Cost effective analysis modeling for the role of a somatostatin analog-Tc99m depreotide (NeoTect) scintigraphy in the evaluation of patients with a solitary pulmonary nodule [abstract]. J Nucl Med 1999; 40(suppl):57P